2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

Formosa Pharmaceuticals, Inc.

Company Presentations

Wednesday, July 22 Company Presentations 1–Pharma

Formosa Pharmaceuticals, Inc.

Company Info

Name /Formosa Pharmaceuticals, Inc.

Address /8F-6, No. 57, Fuxing N. Rd., Songshan District., Taipei 105, Taiwan

Website /www.formosapharma.com

Presenter

Name /Erick Co

Title /Chief Executive Officer

Email /erickco@formosapharma.com

Telephone /(Work) +886 2 2755 7659, ext. 18

Fax /+886 2 2755 3023

Mobile /+886 976266515

Company Type

Biotechnology

About the Company

Formosa Pharmaceuticals is an early-clinical stage biotechnology company with assets in ophthalmology, oncology, and anti-infectives.  Based in Taipei, Taiwan, Formosa Pharmaceuticals has a network of global partners and senior executives with international drug discovery and management experience.  TSY0110, a biosimilar of ado-trastuzumab emtansine, is under development and available for partnering/licensing.  APP13007, a novel therapy for post-surgical ocular pain and inflammation, recently completed Phase 2 studies in the US, and is planned to start Phase 3 trials later this year.  Our proprietary APNT drug delivery formulation platform, from which APP13007 was developed, is available for licensing, CDMO services, or co-development.

Brief Description of main products or services

Formosa Pharmaceuticals offers the following assets for partnering, co-development, or regional licensing:

  • TSY-0110
    1. Biosimilar of the antibody-drug conjugate, Kadcyla® for metastatic breast cancer
    2. Planned Phase 1 clinical trials (EU) in 2021
    3. Full-range manufacturing from payload-linker, bioconjugation, and fill-finish with partner, Formosa Laboratories
  • APP13007
    1. Potent steroid-based eyedrop for post-operative pain and inflammation
    2. Phase 2 clinical trials completed in United States; Phase 3 trials to start in 2020-Q4.
    3. Future potential indications in Uveitis and Dry Eye
  • APP13002
    1. Antibiotic-based eyedrop for infectious eye diseases
    2. Future potential indication in Blepharitis
    3. Potential as monotherapy or combination
  • APNT nanoparticle formulation platform
    1. Tailored for APIs with poor solubility, the APNT platform enhances the dissolution and distribution, thereby improving bioavailability.
    2. Applicable to topical, dermal, inhaler, and oral administration routes
    3. The APNT platform’s characteristics and advantages:
  • Reliable and tunable particle reduction down to sub-100 micron size
  • Stable particle size post-formulation
  • Lower contamination and removable excipients to enable higher concentration
  • Amenable to aseptic filtration
  • Scalable for commercialization
  • MPT0E028
    1. Novel small-molecule HDAC inhibitor for the treatment of solid tumors and tumor-related conditions
    2. Completed Phase 1 in Taiwan

Contact Person

Name /Erick Co

Email /erickco@formosapharma.com

Phone /(Work) +886 2 2755 7659, ext. 18